- Home
- MEGL vs APRE Comparison
MEGL vs APRE Comparison
Compare MEGL & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEGL
- APRE
- Stock Information
- Founded
- MEGL 2016
- APRE 2006
- Country
- MEGL Hong Kong
- APRE United States
- Employees
- MEGL N/A
- APRE N/A
- Industry
- MEGL Finance: Consumer Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MEGL Finance
- APRE Health Care
- Exchange
- MEGL Nasdaq
- APRE Nasdaq
- Market Cap
- MEGL 7.8M
- APRE 8.3M
- IPO Year
- MEGL 2022
- APRE 2019
- Fundamental
- Price
- MEGL $1.30
- APRE $1.31
- Analyst Decision
- MEGL
- APRE Strong Buy
- Analyst Count
- MEGL 0
- APRE 1
- Target Price
- MEGL N/A
- APRE $20.00
- AVG Volume (30 Days)
- MEGL 41.7K
- APRE 131.9K
- Earning Date
- MEGL 12-11-2025
- APRE 11-07-2025
- Dividend Yield
- MEGL N/A
- APRE N/A
- EPS Growth
- MEGL N/A
- APRE N/A
- EPS
- MEGL N/A
- APRE N/A
- Revenue
- MEGL $1,296,394.00
- APRE $841,012.00
- Revenue This Year
- MEGL N/A
- APRE N/A
- Revenue Next Year
- MEGL N/A
- APRE N/A
- P/E Ratio
- MEGL N/A
- APRE N/A
- Revenue Growth
- MEGL N/A
- APRE N/A
- 52 Week Low
- MEGL $1.02
- APRE $1.19
- 52 Week High
- MEGL $5.52
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- MEGL 40.09
- APRE 40.18
- Support Level
- MEGL $1.29
- APRE $1.21
- Resistance Level
- MEGL $1.40
- APRE $1.46
- Average True Range (ATR)
- MEGL 0.09
- APRE 0.08
- MACD
- MEGL -0.01
- APRE -0.02
- Stochastic Oscillator
- MEGL 2.86
- APRE 25.00
About MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The companys offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.